We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

10-Minute Prostate Specific Antigen Test Provides Early Prostate Cancer Warning

By LabMedica International staff writers
Posted on 20 Jan 2025
Image: The Fortel Prostate Screening test detects elevated levels of prostate specific antigen using a finger prick blood sample (Photo courtesy of Biomerica)
Image: The Fortel Prostate Screening test detects elevated levels of prostate specific antigen using a finger prick blood sample (Photo courtesy of Biomerica)

Prostate cancer is the second most common cancer among men globally, with 1.4 million new cases diagnosed and 375,000 deaths reported worldwide in 2020. Alarmingly, a new case is diagnosed every two minutes. While significant progress has been made in early detection and research, prostate cancer remains a major public health concern. Elevated levels of prostate-specific antigen (PSA), a substance produced by the prostate and released in trace amounts into the bloodstream, may indicate potential prostate disease. Now, a new test designed to detect elevated PSA levels from a finger-prick blood sample could serve as an early warning sign for prostate cancer.

Biomerica’s (Irvine, CA, USA) Fortel PSA Screening Test is a simple, user-friendly diagnostic tool that provides accurate results within just 10 minutes using a finger-prick blood sample. By measuring elevated PSA levels, a known early indicator of prostate disease, the test helps with the early detection of prostate cancer and other related conditions. This accessible and rapid method aims to improve proactive health management, ease the burden on healthcare systems, and enhance patient outcomes. The Fortel PSA test has shown exceptional performance in rigorous evaluations, with a study reporting 100% sensitivity, 95% specificity, and 97.5% accuracy, aligning with laboratory reference methods. Further studies have validated the test’s effectiveness, showing 97.2% sensitivity, 96.2% specificity, and 96.7% accuracy. These promising results highlight the Fortel PSA test as a reliable and efficient tool for early detection.


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gel Cards
DG Gel Cards
New
Human Estradiol Assay
Human Estradiol CLIA Kit

Latest Molecular Diagnostics News

New Test Detects Early-Stage Solid Tumors Using Only Blood Sample
20 Jan 2025  |   Molecular Diagnostics

AI-Enhanced Cell-Based Blood Tests to Improve Predictive Accuracy for Complex Transplant Outcomes
20 Jan 2025  |   Molecular Diagnostics

Non-Invasive Blood Test for Endometriosis Could Replace Surgical Procedures
20 Jan 2025  |   Molecular Diagnostics